Buchumschlag

Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT

Long-term locoregional control in locally advanced squamous cell carcinoma of the head and neck (SCCHN) remains challenging. While recent years have seen various approaches to improve outcome by intensification of treatment schedules through introduction of novel induction and combination chemothera...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Jensen, Alexandra (VerfasserIn) , Krauß, Jürgen (VerfasserIn) , Potthoff, Karin (VerfasserIn) , Desta, Almaz (VerfasserIn) , Habl, Gregor (VerfasserIn) , Mavtratzas, Athanasios (VerfasserIn) , Windemuth-Kiesselbach, Christine (VerfasserIn) , Debus, Jürgen (VerfasserIn) , Münter, Marc (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 19 May 2011
In: BMC cancer
Year: 2011, Jahrgang: 11, Pages: 1-11
ISSN:1471-2407
DOI:10.1186/1471-2407-11-182
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1471-2407-11-182
Volltext
Verfasserangaben:Alexandra D. Jensen, Jürgen Krauss, Karin Potthoff, Almaz Desta, Gregor Habl, Athanasios Mavtratzas, Christine Windemuth-Kiesselbach, Jürgen Debus and Marc W. Münter
Beschreibung
Zusammenfassung:Long-term locoregional control in locally advanced squamous cell carcinoma of the head and neck (SCCHN) remains challenging. While recent years have seen various approaches to improve outcome by intensification of treatment schedules through introduction of novel induction and combination chemotherapy regimen and altered fractionation regimen, patient tolerance to higher treatment intensities is limited by accompanying side-effects. Combined radioimmunotherapy with cetuximab as well as modern radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) and carbon ion therapy (C12) are able to limit toxicity while maintaining treatment effects. In order to achieve maximum efficacy with yet acceptable toxicity, this sequential phase II trial combines induction chemotherapy with docetaxel, cisplatin, and 5-FU (TPF) followed by radioimmunotherapy with cetuximab as IMRT plus carbon ion boost. We expect this approach to result in increased cure rates with yet manageable accompanying toxicity.
Beschreibung:Gesehen am 05.07.2022
Beschreibung:Online Resource
ISSN:1471-2407
DOI:10.1186/1471-2407-11-182

Ähnliche Einträge